Replies to post #122181 on Amarantus Bioscience Holdings Inc (AMBS)

[christjamin]

Let us face it. It is not easy to get clean funding at this stage. Our best chance I would think lies with ESS. I mean I could see national/ foreign entity interested in ESS and decides to fund it. If such instrument shows up the question is how much will they get. They will want to share the pie. That begs the question: are we better off going it alone via shares sale or Via JV? Nothing is free..I see less chance that JV happening with Eltoprazine (CNS cures are too risky) or MANF(too far from from maturity)..
Either way, patient investors will to go through pain and willing to average cost may be highly rewarded..
Patience is virtue, blind patience is not wisdom..

[JPetroInc]

Findings on Neurobiology from V. Ghiglieri and Colleagues Provide New Insights (Modulation of Serotonergic Transmission by Eltoprazine in...

02/04/2016 | 01:51pm US/Eastern

http://www.4-traders.com/SYSTEM-RESEARCH-CO-LTD-11551378/news/SYSTEM-RESEARCH-Findings-on-Neurobiology-from-V-Ghiglieri-and-Colleagues-Provide-New-Insights-Mo-21801427/

Findings on Neurobiology from V. Ghiglieri and Colleagues Provide New Insights (Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms)

By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on Nervous System Research. According to news originating from Caserta, Italy, by NewsRx correspondents, research stated, "L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs) represent the main side effect of Parkinson's Disease (PD) therapy. Among the various pharmacological targets for novel therapeutic approaches, the serotonergic system represents a promising one."

Our news journalists obtained a quote from the research, "In experimental models of PD and in PD patients the development of abnormal involuntary movements (AIMs) and LIDs, respectively, is accompanied by the impairment of bidirectional synaptic plasticity in key structures such as striatum. Recently, it has been shown that the 5-HT1A/1B receptor agonist, eltoprazine, significantly decreased LIDs in experimental PD and human patients. Despite the fact that several papers have tested this and other serotonergic drugs, nothing is known about the electrophysiological consequences on this combined serotonin receptors modulation at striatal neurons. The present study demonstrates that activation of 5-HT1A/1B receptors reduces AlMs via the restoration of Long-Term Potentiation (LTP) and synaptic depotentiation in a sub-set of striatal spiny projection neurons (SPNs). This recovery is associated with the normalization of D1 receptor-dependent cAMP/PKA and ERK/mTORC signaling pathways, and the recovery of NMDA receptor subunits balance, indicating these events as key elements in AIMs induction. Moreover, we analyzed whether the manipulation of the serotonergic system might affect motor behavior and cognitive performances. We found that a defect in locomotor activity in parkinsonian and L-DOPA-treated rats was reversed by eltoprazine treatment."

According to the news editors, the research concluded: "Conversely, the impairment in the striatal-dependent learning was found exacerbated in L-DOPA-treated rats and eltoprazine failed to recover it."

For more information on this research see: Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. Neurobiology of Disease, 2016;86():140-153. Neurobiology of Disease can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Neurobiology of Disease - www.journals.elsevier.com/neurobiology-of-disease/)

The news correspondents report that additional information may be obtained from V. Ghiglieri, SUN, Dipartimento Sci & Tecnol Ambientali Biol & Farma, I-81100 Caserta, Italy. Additional authors for this research include D. Mineo, A. Vannelli, F. Cacace, M. Mancini, V. Pendolino, F. Napolitano, A. di Maio, M. Mellone, J. Stanic, E. Tronci, C. Fidalgo, R. Stancampiano, M. Carta, P. Calabresi, F. Gardoni, A. Usiello and B. Picconi (see also Nervous System Research).

Keywords for this news article include: Italy, Europe, Caserta, Nervous System Research

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

[Inoviorulez]

I don't know why people are so quick to judge JP on his stance for Amarantus. What he says is the truth. All the investors want to see is the CEO being honest -- which he hasn't delivered on anything promised -- and to find financing that is not toxic.

These 2 items have killed the share price. If both things magically turn around then the company might have a chance but I don't see that happening unfortunately with Gerald at the helm of the CEO role.